Literature DB >> 24371067

Fitness and virulence of a coxsackievirus mutant that can circumnavigate the need for phosphatidylinositol 4-kinase class III beta.

Hendrik Jan Thibaut1, Hilde M van der Schaar, Kjerstin H W Lanke, Erik Verbeken, Martin Andrews, Pieter Leyssen, Johan Neyts, Frank J M van Kuppeveld.   

Abstract

Coxsackieviruses require phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) for replication but can bypass this need by an H57Y mutation in protein 3A (3A-H57Y). We show that mutant coxsackievirus is not outcompeted by wild-type virus during 10 passages in vitro. In mice, the mutant virus proved as virulent as wild-type virus, even when mice were treated with a PI4KIIIβ inhibitor. Our data suggest that upon emergence, the 3A-H57Y mutant has the fitness to establish a resistant population with a virulence similar to that of wild-type virus.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24371067      PMCID: PMC3958056          DOI: 10.1128/JVI.03177-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  10 in total

1.  Mutations in the nonstructural protein 3A confer resistance to the novel enterovirus replication inhibitor TTP-8307.

Authors:  Armando M De Palma; Hendrik Jan Thibaut; Lonneke van der Linden; Kjerstin Lanke; Ward Heggermont; Stephen Ireland; Robert Andrews; Murty Arimilli; Taleb H Al-Tel; Erik De Clercq; Frank van Kuppeveld; Johan Neyts
Journal:  Antimicrob Agents Chemother       Date:  2009-02-23       Impact factor: 5.191

2.  Inflammatory rather than infectious insults play a role in exocrine tissue damage in a mouse model for coxsackievirus B4-induced pancreatitis.

Authors:  Armando M De Palma; Hendrik J Thibaut; Sandra Li; Ilse Van Aelst; Chris Dillen; Melissa Swinnen; Erik Verbeken; Johan Neyts; Ghislain Opdenakker
Journal:  J Pathol       Date:  2009-04       Impact factor: 7.996

3.  Sequence determinants of 3A-mediated resistance to enviroxime in rhinoviruses and enteroviruses.

Authors:  B A Heinz; L M Vance
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

4.  A bifunctional anti-enterovirus compound that inhibits replication and the early stage of enterovirus 71 infection.

Authors:  Minetaro Arita; Yutaka Takebe; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Gen Virol       Date:  2010-07-21       Impact factor: 3.891

5.  The antiviral compound enviroxime targets the 3A coding region of rhinovirus and poliovirus.

Authors:  B A Heinz; L M Vance
Journal:  J Virol       Date:  1995-07       Impact factor: 5.103

6.  A novel, broad-spectrum inhibitor of enterovirus replication that targets host cell factor phosphatidylinositol 4-kinase IIIβ.

Authors:  Hilde M van der Schaar; Pieter Leyssen; Hendrik J Thibaut; Armando de Palma; Lonneke van der Linden; Kjerstin H W Lanke; Céline Lacroix; Erik Verbeken; Katja Conrath; Angus M Macleod; Dale R Mitchell; Nicholas J Palmer; Hervé van de Poël; Martin Andrews; Johan Neyts; Frank J M van Kuppeveld
Journal:  Antimicrob Agents Chemother       Date:  2013-07-29       Impact factor: 5.191

7.  Increased gelatinase B/matrix metalloproteinase 9 (MMP-9) activity in a murine model of acute coxsackievirus B4-induced pancreatitis.

Authors:  Armando M De Palma; Erik Verbeken; Ilse Van Aelst; Philippe E Van den Steen; Ghislain Opdenakker; Johan Neyts
Journal:  Virology       Date:  2008-10-16       Impact factor: 3.616

8.  Cellular kinase inhibitors that suppress enterovirus replication have a conserved target in viral protein 3A similar to that of enviroxime.

Authors:  Minetaro Arita; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Gen Virol       Date:  2009-05-13       Impact factor: 3.891

9.  Phosphatidylinositol 4-kinase III beta is a target of enviroxime-like compounds for antipoliovirus activity.

Authors:  Minetaro Arita; Hirotatsu Kojima; Tetsuo Nagano; Takayoshi Okabe; Takaji Wakita; Hiroyuki Shimizu
Journal:  J Virol       Date:  2010-12-22       Impact factor: 6.549

10.  Coxsackievirus mutants that can bypass host factor PI4KIIIβ and the need for high levels of PI4P lipids for replication.

Authors:  Hilde M van der Schaar; Lonneke van der Linden; Kjerstin H W Lanke; Jeroen R P M Strating; Gerhard Pürstinger; Erik de Vries; Cornelis A M de Haan; Johan Neyts; Frank J M van Kuppeveld
Journal:  Cell Res       Date:  2012-09-04       Impact factor: 46.297

  10 in total
  6 in total

1.  A large scale high-throughput screen identifies chemical inhibitors of phosphatidylinositol 4-kinase type II alpha.

Authors:  Nivedita Sengupta; Marko Jović; Elena Barnaeva; David W Kim; Xin Hu; Noel Southall; Milan Dejmek; Ivana Mejdrova; Radim Nencka; Adriana Baumlova; Dominika Chalupska; Evzen Boura; Marc Ferrer; Juan Marugan; Tamas Balla
Journal:  J Lipid Res       Date:  2019-01-09       Impact factor: 5.922

2.  Enterovirus 3A Facilitates Viral Replication by Promoting Phosphatidylinositol 4-Kinase IIIβ-ACBD3 Interaction.

Authors:  Xia Xiao; Xiaobo Lei; Zhenzhen Zhang; Yijie Ma; Jianli Qi; Chao Wu; Yan Xiao; Li Li; Bin He; Jianwei Wang
Journal:  J Virol       Date:  2017-09-12       Impact factor: 5.103

Review 3.  Rewiring of cellular membrane homeostasis by picornaviruses.

Authors:  George A Belov; Elizabeth Sztul
Journal:  J Virol       Date:  2014-06-11       Impact factor: 5.103

4.  The Golgi protein ACBD3 facilitates Enterovirus 71 replication by interacting with 3A.

Authors:  Xiaobo Lei; Xia Xiao; Zhenzhen Zhang; Yijie Ma; Jianli Qi; Chao Wu; Yan Xiao; Zhuo Zhou; Bin He; Jianwei Wang
Journal:  Sci Rep       Date:  2017-03-17       Impact factor: 4.379

Review 5.  Ultrastructure of the replication sites of positive-strand RNA viruses.

Authors:  Christian Harak; Volker Lohmann
Journal:  Virology       Date:  2015-03-06       Impact factor: 3.616

Review 6.  Fat(al) attraction: Picornaviruses Usurp Lipid Transfer at Membrane Contact Sites to Create Replication Organelles.

Authors:  Hilde M van der Schaar; Cristina M Dorobantu; Lucian Albulescu; Jeroen R P M Strating; Frank J M van Kuppeveld
Journal:  Trends Microbiol       Date:  2016-03-22       Impact factor: 17.079

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.